STAT3 and glioblastoma: Trials investigating the safety and efficacy of STAT3 and PD-1 blockade (e.g., NCT02851004, NCT02467361, NCT02983578, and NCT03421353) in various solid malignancies are underway, and there is hope that insights gained from these may inform trial design for GBM.